After the treatment , the rate of changes of ovarian mass volume ( among them , at 12 weeks after the first injection , the median was -55.83 % in the test group , -68.22 % in the control group , P = 0.336 ) , the distinct improvement rate of symptom scores and pelvic signs during non-menstrual days [ among them , at 12 weeks after the first injection , the rate of lower abdomen pain was 47.5 % ( 48/101 ) in the test group , 44.0 % ( 44/100 ) in the control group , P = 0.881 ] , the hormone ( E2 , FSH , LH ) levels [ among them , at 12 weeks after the first injection , the serum level of E2 , was ( 3338 ) pmol/L in the test group , ( 3840 ) pmol/L in the control group , P = 0.414 ; the serum level of FSH , was ( 5.12.8 ) U/L in the test group , ( 5.32.3 ) U/L in the control group , P = 0.666 ; the serum level of LH , was ( 0.60.8 ) U/L in the test group , ( 0.60.9 ) U/L in the control group , P = 0.907 ] , had no statistically significant difference between the two groups ( all P > 0.05 ) .